ALS (Lou Gehrig's Disease) clinical trials in Arizona
16 active ALS (Lou Gehrig's Disease) trials with a site in Arizona. Describe your situation to see which ones look like a fit.
- Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
- Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
- Study of COYA 302 for the Treatment of ALS
- PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
- Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
- RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- PREVENT ALL ALS Study
- ASSESS ALL ALS Study
- EIM Via the Myolex mScan as an ALS Biomarker
- Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
- Precise Robotically IMplanted Brain-Computer InterfacE
- Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)
- Safety Study of XT-150 in Participants With ALS
- Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?
- Control of Assistive Devices Via Brain-Computer Interface Technology
- HEALEY ALS Platform Trial - Master Protocol
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.